Navigation Links
Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
Date:1/29/2013

In three to six months of life, this genetic alteration in mice similar to that occurred in human causes a rapid degeneration in the lower limbs to death for cardiac arrest.

For the first time in the world, researchers at the Center for Biomedical Research of the University of Granada have created mice with a genetic mutation inducing a deficiency in the coenzyme Q10, a rare mitochondrial disease prevailingly affecting children. These mutant mice which lack the Coq9 gene will be "a valuable tool for the study and treatment of metabolic encephalopathies and neuromuscular diseases", the researchers state.

Coenzyme Q10 (CoQ10) is a molecule produced in body cells, which functions are crucial to cell metabolism. Their best-known function is their generating energy used by cells and their antioxidant activity. In human, defects in the biosynthetic route cause CoQ10 deficiency, resulting in a syndrome with very heterogeneous symptoms.

To better understand the pathological mechanisms of this disease and learn about the biosynthetic pathway of CoQ, the University of Granada researchers conducted a three-year study to generate mice with a mutation in a gene (Coq9) similar to that found in humans. This gene codifies a protein involved in CoQ biosynthesis.

Lower Limb Paralysis

Accordikng to professor Luis Carlos Lpez Garca the principal investigator of this study states, "mice with a Coq9 mutation develop a severe encephalomyopathy inducing neural death, astrogliosis and vacuolation of the brain. At three to six months, these mice undergo a rapid degeneration causing lower limp paralysis and death for cardiac arrest. In molecular terms, CoQ deficiency in mice impairs the mitochondrial mechanisms of bioenergy production in the brain, causing a severe bioenergetic deficiency and a slight increase in oxidative damage".

The CoQ9-deficient mutant mouse model generated at the University of Granada "is the first model of CoQ9-deficient mutant mice with mitochondrial encephalomyopathy created worldwide. Currently, there is not any therapy for neuromuscular diseases associated with CoQ10 deficiency, and this mutant model might be useful in the development of an effective therapy for such diseases. In addition, as CoQ10 is also used as a nutritional supplement and in the cosmetics industry, "the CoQ9-deficient mutant mouse model is very useful in the assessment of the effectiveness of nutritional supplements and cosmetics".

The results of this research study which received financial support from CEI BioTic Granad, the Spanish Ministry of Economy and Competitiveness, the Andalusian Regional Government and the Marie Curie program have been recently published in the prestigious journal Human Molecular Genetics. Researchers from the National Cardiovascular Research Center (CNIC) also participated in the study.


'/>"/>
Contact: Luis Carlos Lpez Garca
luisca@ugr.es
University of Granada
Source:Eurekalert  

Related biology news :

1. In breast cancer metastasis, researchers identify possible drug target
2. Clemson University researchers: What happens to peaches when the chill is gone?
3. Socially isolated rats are more vulnerable to addiction, report researchers
4. UT Dallas researchers awarded $4.3 million to create next-generation technologies
5. Vitamin D holds promise in battling a deadly breast cancer, Saint Louis University researchers say
6. Researchers analyse rock dissolving method of geoengineering
7. Researchers show how cells DNA repair machinery can destroy viruses
8. Researchers turn one form of neuron into another in the brain
9. UGA researchers invent new material for warm-white LEDs
10. RUB researchers find over active enzyme in failing hearts
11. Researchers attack HIVs final defenses before drug-resistant mutations emerge
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... 2016 , ... The American Medical Informatics Association (AMIA) responded ... Coordinator for Health IT (ONC) outlining a measurement approach to interoperability that focuses ... and where it was needed. The organization of health informatics professionals said a ...
(Date:5/25/2016)... SALT LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... create efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been ... served as WEDI’s interim CEO since January 2016. As an executive leader with more ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ., ... artificial intelligence, real-time decision support tools in the emergency room, ... the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology Week, ... David Intercontinental Hotel in Tel Aviv, Israel ...
Breaking Biology Technology: